Novo Nordisk A/ S stock (DK0062498333): Ozempic boom meets fresh obesity data and US pricing debate

Novo Nordisk A/S remains one of the most closely watched healthcare stocks as new clinical data around its obesity and diabetes franchise, including Wegovy and Ozempic, continue to shape expectations for long-term growth and potential pricing pressure in key markets such as the United States, according to recent company updates and financial media coverage in May and June 2026.

As of: 09.06.2026

By the editorial team – specialized in equity coverage.

Novo Nordisk A/S: core business model

Novo Nordisk A/S is a global pharmaceutical group focused on chronic diseases such as diabetes, obesity and rare endocrine disorders, with a business model that combines proprietary research, large-scale biologics manufacturing and global commercialization through affiliates and partners in major healthcare markets. The company generates most of its revenue from prescription drugs reimbursed by public and private payers.

Historically, Novo Nordisk built its franchise around insulin and other diabetes treatments, evolving into one of the world’s largest producers of insulin and GLP-1 receptor agonists for type 2 diabetes patients. Over time, the strategy shifted toward higher-value, patent-protected therapies that offer improved glucose control and added benefits such as weight reduction, which helped drive margin expansion and pricing power over the last decade in key markets.

In recent years, the company’s business model has become increasingly centered on GLP-1 based therapies such as Ozempic for type 2 diabetes and Wegovy for obesity, which have seen significant uptake among patients and payers amid rising global obesity and metabolic disease burdens. These therapies, typically injectable and administered weekly, are supported by long-term outcome data and high barriers to entry due to complex manufacturing and regulatory requirements.

Beyond diabetes and obesity, Novo Nordisk runs smaller but strategically important franchises in rare diseases, including hemophilia and growth hormone disorders, which diversify its earnings base while leveraging biologics expertise. These segments are not as large as the GLP-1 business but can offer attractive margins because of specialized products and relatively limited competition in rare disease indications.

The company’s research and development efforts emphasize large clinical programs designed to expand indications and demonstrate broader outcome benefits, such as cardiovascular risk reduction and kidney protection. By generating data in additional disease areas, Novo Nordisk aims to sustain the lifecycle of its GLP-1 assets and justify reimbursement at higher price points in health systems that increasingly demand proof of long-term value.

Main revenue and product drivers for Novo Nordisk A/S

Novo Nordisk’s current revenue mix is dominated by GLP-1 therapies for type 2 diabetes and obesity, led by Ozempic and Wegovy, which have recorded strong volume growth in the United States and other developed markets. These drugs address large patient populations and benefit from increasing awareness of the links between obesity, diabetes and cardiovascular disease, supporting continued demand in primary care and specialist settings.

Ozempic, administered once weekly, is indicated for type 2 diabetes management and has become a key prescription choice for physicians seeking both glucose control and weight benefits. The product’s growth has been supported by clinical outcome data and ongoing promotional efforts in the US, where commercial insurance coverage plays a crucial role in uptake. Increasingly, real-world evidence from US practice is being used to support payer discussions and clinical guidelines.

Wegovy, also a GLP-1 based therapy, is targeted at obesity treatment and has attracted significant attention due to its weight-loss efficacy demonstrated in clinical trials. In the United States, Wegovy’s growth is closely tied to coverage decisions by commercial insurers and employer plans, as obesity drugs historically have not been reimbursed as broadly as diabetes medications. Nonetheless, rising recognition of obesity as a chronic disease is gradually supporting broader discussions about coverage and long-term health economics.

The company’s legacy insulin portfolio, while facing pricing pressure and biosimilar competition in markets like the US, remains a substantial revenue contributor, particularly in regions where insulin penetration is still increasing. However, pricing reforms, discount negotiations with pharmacy benefit managers and the potential for further regulatory interventions in the US continue to limit growth in that segment and shift strategic focus toward higher-margin GLP-1 products.

In addition to insulin and GLP-1 products, Novo Nordisk generates sales from other diabetes therapies, including oral antidiabetic agents and combinations, as well as from its rare disease portfolio. These segments contribute to diversification and can offer more stable price environments compared with the high-profile US insulin market, although they do not match the scale of GLP-1 blockbuster revenues.

Future revenue growth is expected to depend heavily on the ability to expand GLP-1 capacity and maintain supply reliability, given the manufacturing complexity and strong global demand. This includes investments in production sites, partnerships with contract manufacturers and continuous process improvements. For US investors, the ability to meet demand has direct implications for quarterly revenue trajectories and market share relative to current and future competitors.

Why Novo Nordisk A/S matters for US investors

For US investors, Novo Nordisk A/S is relevant primarily through its American depositary receipts listed on the New York Stock Exchange under the ticker NVO, which offer direct exposure to trends in diabetes and obesity treatment. These ADRs allow participation in the growth of GLP-1 based therapies that are widely prescribed in the US, where obesity and type 2 diabetes prevalence remain high compared with many other developed markets.

The company’s US performance is closely tied to reimbursement decisions by commercial insurers, Medicare-related policies and negotiations with pharmacy benefit managers, which influence net prices and formulary positioning. Changes in US healthcare regulation, such as potential drug price negotiation frameworks or caps on patient out-of-pocket costs, can therefore have a meaningful impact on Novo Nordisk’s profitability and growth prospects in its largest market for GLP-1 products.

Competitive dynamics in the US further heighten the importance of the market for Novo Nordisk shareholders. Rival pharmaceutical companies are advancing their own GLP-1 and next-generation obesity candidates, leading to expectations of more competition in the medium term. For US-focused portfolios, the timing and impact of competing launches, potential new oral formulations and combination therapies are key elements when assessing how durable Novo Nordisk’s current leadership position might be.

Currency fluctuations between the Danish krone and the US dollar also play a role for US investors, as reported results in Danish currency must be translated when assessing the value of the US-listed ADRs. While day-to-day stock movements are driven mainly by drug data, earnings reports and regulatory developments, exchange-rate trends can influence the longer-term return profile for dollar-based investors in this European healthcare leader.

Conclusion

Novo Nordisk A/S has evolved from a traditional insulin producer into a global leader in GLP-1 based therapies for diabetes and obesity, with Ozempic and Wegovy at the center of its current growth story in markets including the United States. The company’s focus on large-scale clinical data, supply expansion and diversification into related chronic conditions underpins expectations for continued relevance in metabolic health. At the same time, US pricing debates, competitive pipelines and regulatory uncertainty remain important factors that could influence margins and market share and are therefore monitored closely by investors following this high-profile healthcare stock.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.